Immunotherapy discussions at ASH 2017
Raúl Córdoba et al.
Challenges associated with long-term therapies in CLL
From the bench to bedside: AML treatment
ASH 2017 top picks: Phase III trials, antibody-drug conjugates and CAR T-cells
How to manage relapsed/refractory MCL - new agents and unmet needs